Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG Somatropin in Children With Growth Hormone Deficiency
NCT03249480Phase 4Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peg-somatropin in growth hormone deficiency (GHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Height Standard Deviation Score for Chronological Age and Change of yearly growth velocity at 26 weeks. Status: unknown.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03249480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249480.